Northern Trust Corp Increases Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Northern Trust Corp boosted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 18.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 717,161 shares of the specialty pharmaceutical company’s stock after purchasing an additional 110,867 shares during the quarter. Northern Trust Corp owned approximately 1.30% of Supernus Pharmaceuticals worth $25,933,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Summit Investment Advisors Inc. increased its holdings in Supernus Pharmaceuticals by 7.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company’s stock worth $190,000 after purchasing an additional 369 shares during the last quarter. Bank of Montreal Can increased its holdings in Supernus Pharmaceuticals by 6.6% during the 4th quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company’s stock worth $275,000 after purchasing an additional 473 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in Supernus Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock worth $800,000 after purchasing an additional 560 shares during the last quarter. HighTower Advisors LLC increased its holdings in Supernus Pharmaceuticals by 7.3% during the 4th quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company’s stock worth $330,000 after purchasing an additional 624 shares during the last quarter. Finally, Bridge City Capital LLC increased its holdings in Supernus Pharmaceuticals by 0.8% during the 4th quarter. Bridge City Capital LLC now owns 94,997 shares of the specialty pharmaceutical company’s stock worth $3,435,000 after purchasing an additional 761 shares during the last quarter.

Insider Activity

In other news, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 9.30% of the company’s stock.

Analyst Upgrades and Downgrades

SUPN has been the topic of several analyst reports. Cantor Fitzgerald restated a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday.

Supernus Pharmaceuticals Trading Up 0.5%

Shares of NASDAQ SUPN opened at $31.70 on Monday. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $40.28. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of 29.63 and a beta of 0.74. The business has a 50 day simple moving average of $31.86 and a 200-day simple moving average of $34.90.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.